Immune-mediating and immunosuppressive pharmacotherapies for proliferative lupus nephritis

被引：0
作者：
Moroni, Gabriella [1 ,2 ]
Reggiani, Francesco [1 ,2 ]
Ponticelli, Claudio
机构：
[1] IRCCS Humanitas Res Hosp, Nephrol & Dialysis Unit, Via Manzoni 56, I-20089 Milan, Italy
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2024年 / 25卷 / 15期
关键词：
Lupus nephritis; immunosuppressive therapies; cytotoxic drugs; monoclonal antibodies; induction therapy; maintenance therapy; remission; glucocorticoids; CHILDHOOD-ONSET LUPUS; LONG-TERM OUTCOMES; MYCOPHENOLATE-MOFETIL; MAINTENANCE THERAPY; INTRAVENOUS CYCLOPHOSPHAMIDE; INDUCTION TREATMENT; CONTROLLED-TRIAL; PULSE CYCLOPHOSPHAMIDE; SUSTAINED AMENORRHEA; MULTITARGET THERAPY;
D O I：
10.1080/14656566.2024.2416038
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
IntroductionProliferative lupus nephritis is a common and severe complication of systemic lupus erythematosus. Affected patients are at an increased risk of developing chronic kidney disease, end-stage kidney disease, and extra-renal comorbidities. In recent years, the prognosis for patients with proliferative lupus nephritis has improved thanks to advancements in management regimens. Despite these advances, lupus nephritis continues to present therapeutic complexities and unmet needs.Areas coveredResearch was conducted across major databases to identify the most relevant articles pertaining to immune-mediating and immunosuppressive therapies in lupus nephritis.Expert opinionThe prognosis for patients with proliferative lupus nephritis remains severe. Some drugs used in this disease may be unable to control activity, and most of them have a low therapeutic index and may cause severe and life-threatening side effects. Nonetheless, better management of traditional drugs and the introduction of novel therapies have improved renal prognosis and reduced local and systemic adverse events in patients with proliferative lupus nephritis.
引用
收藏
页码：2061 / 2076
页数：16
相关论文
共 50 条
[41]   Defining the Role of Mycophenolate Mofetil in the Treatment of Proliferative Lupus Nephritis [J].
Oliver Dr Lenz ;
Alessia Fornoni ;
Gabriel Contreras .
Drugs, 2005, 65 :2429-2436
[42]   Autoantibodies in lupus nephritis useful in distinguishing proliferative nephritis from membranous nephritis [J].
Asanuma, Yuko ;
Nozawa, Kazuhisa ;
Matsushita, Masakazu ;
Kusaoi, Makio ;
Abe, Yoshiyuki ;
Yamaji, Ken ;
Tamura, Naoto .
MODERN RHEUMATOLOGY, 2023, 33 (06) :1110-1116
[43]   Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients [J].
Szeto, Cheuk-Chun ;
Tam, Lai-Shan .
NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (12) :672-673
[44]   Disease severity of proliferative lupus nephritis in Maghrebians [J].
Tamirou, F. ;
Costedoat-Chalumeau, N. ;
Medkouri, G. ;
Daugas, E. ;
Hachulla, E. ;
Jourde-Chiche, N. ;
Karras, A. ;
le Guern, V. ;
Gnemmi, V. ;
Jadoul, M. ;
Houssiau, F. A. .
LUPUS, 2018, 27 (08) :1387-1392
[45]   Assessment of renal response in Tunisian patients with proliferative lupus nephritis under three different induction immunosuppressive agents: A prognostic retrospective study [J].
Somai, Mehdi ;
Daoud, Fatma ;
Arbaoui, Ibrahim ;
Boukhzar, Rihem ;
Ben Dhaou, Besma ;
Bellali, Hedia ;
Boussema, Fatma ;
Rachdi, Imene ;
Aydi, Zohra .
LUPUS, 2024, 33 (14) :1615-1625
[46]   Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? [J].
Grootscholten, C ;
Berden, JHM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (06) :1465-1469
[47]   Treatment of Childhood-onset Proliferative Lupus Nephritis in the 21st Century: A Call to Catch Up With the Evidence [J].
Noone, Damien G. ;
Silverman, Earl D. .
JOURNAL OF RHEUMATOLOGY, 2022, 49 (06) :552-554
[48]   Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment [J].
Zickert, Agneta ;
Lannfelt, Klas ;
Mende, Jan Schmidt ;
Sundelin, Birgitta ;
Gunnarsson, Iva .
RHEUMATOLOGY, 2021, 60 (07) :3443-3450
[49]   Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis [J].
Oh Chan Kwon ;
Jung Hwan Park ;
Hyeong-Cheon Park ;
Seung Min Jung ;
Sang-Won Lee ;
Jason Jungsik Song ;
Yong-Beom Park ;
Min-Chan Park .
Arthritis Research & Therapy, 22
[50]   Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis [J].
Kwon, Oh Chan ;
Park, Jung Hwan ;
Park, Hyeong-Cheon ;
Jung, Seung Min ;
Lee, Sang-Won ;
Song, Jason Jungsik ;
Park, Yong-Beom ;
Park, Min-Chan .
ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
12345